These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 21382861)
1. B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica and multiple sclerosis. Zhang H Mult Scler; 2011 May; 17(5):639-40; author reply 641. PubMed ID: 21382861 [No Abstract] [Full Text] [Related]
2. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Okada K; Matsushita T; Kira J; Tsuji S Neurology; 2010 Jan; 74(2):177-8. PubMed ID: 20065253 [No Abstract] [Full Text] [Related]
3. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Uzawa A; Mori M; Masuda S; Kuwabara S Arch Neurol; 2011 Jul; 68(7):913-7. PubMed ID: 21747031 [TBL] [Abstract][Full Text] [Related]
4. [Investigation of B-cell activating factor in serum and cerebrospinal fluid of patients with neuromyelitis optical]. Yang F; Huang D; Wu W Nan Fang Yi Ke Da Xue Xue Bao; 2015 Mar; 35(3):380-3. PubMed ID: 25818784 [TBL] [Abstract][Full Text] [Related]
5. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. Narikawa K; Misu T; Fujihara K; Nakashima I; Sato S; Itoyama Y J Neuroimmunol; 2004 Apr; 149(1-2):182-6. PubMed ID: 15020078 [TBL] [Abstract][Full Text] [Related]
6. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Vaknin-Dembinsky A; Brill L; Orpaz N; Abramsky O; Karussis D Mult Scler; 2010 Dec; 16(12):1453-7. PubMed ID: 20935029 [TBL] [Abstract][Full Text] [Related]
7. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Petereit HF; Rubbert-Roth A Mult Scler; 2009 Feb; 15(2):189-92. PubMed ID: 18971221 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica. Jiang Y; Yang Y; Zhang B; Peng F; Bao J; Hu X Neuro Endocrinol Lett; 2009 Mar; 30(1):85-90. PubMed ID: 19300400 [TBL] [Abstract][Full Text] [Related]
9. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Uzawa A; Mori M; Arai K; Sato Y; Hayakawa S; Masuda S; Taniguchi J; Kuwabara S Mult Scler; 2010 Dec; 16(12):1443-52. PubMed ID: 20739337 [TBL] [Abstract][Full Text] [Related]
10. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier. Hosokawa T; Nakajima H; Doi Y; Sugino M; Kimura F; Hanafusa T; Takahashi T J Neuroimmunol; 2011 Jul; 236(1-2):81-6. PubMed ID: 21621856 [TBL] [Abstract][Full Text] [Related]
11. Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. Masuda H; Mori M; Uchida T; Uzawa A; Ohtani R; Kuwabara S J Neuroimmunol; 2017 Apr; 305():102-107. PubMed ID: 28284329 [TBL] [Abstract][Full Text] [Related]
12. NMO-IgG in the diagnosis of neuromyelitis optica. Jarius S; Franciotta D; Bergamaschi R; Wright H; Littleton E; Palace J; Hohlfeld R; Vincent A Neurology; 2007 Mar; 68(13):1076-7. PubMed ID: 17287449 [No Abstract] [Full Text] [Related]
13. [CSF-protein in neuromyelitis optica (author's transl)]. Krause KH; Berlit P; Schmitt HP; von Kummer R Fortschr Neurol Psychiatr; 1982 Apr; 50(4):133-8. PubMed ID: 7095722 [No Abstract] [Full Text] [Related]
14. [Neuromyelitis optica IgG and related clinical features of patients with neuromyelitis optica]. You XF; Ye J; Li CJ; Liao ZY; Sun H Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(35):2477-80. PubMed ID: 21092475 [TBL] [Abstract][Full Text] [Related]
15. Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders. Shu Y; Li H; Zhang L; Wang Y; Long Y; Li R; Qiu W; Lu Z; Hu X; Peng F Brain Behav; 2017 Jan; 7(1):e00584. PubMed ID: 28127508 [TBL] [Abstract][Full Text] [Related]
16. [Diagnostic criteria in acute neuromyelitis]. Panea C; Petrescu S; Monica P; Voinea L; Dascălu AM; Nicolae M; Ungureanu E; Panca A; Grădinaru S Oftalmologia; 2007; 51(4):116-20. PubMed ID: 18543687 [TBL] [Abstract][Full Text] [Related]
17. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. Wang H; Wang K; Zhong X; Qiu W; Dai Y; Wu A; Hu X J Clin Immunol; 2012 Oct; 32(5):1007-11. PubMed ID: 22644841 [TBL] [Abstract][Full Text] [Related]
19. Importance of cerebrospinal fluid examination in differential diagnosis of Devic's neuromyelitis optica by multiple sclerosis. Bergamaschi R Neurol Sci; 2003 Oct; 24(3):95-6. PubMed ID: 14600818 [No Abstract] [Full Text] [Related]
20. High CSF neurofilament heavy chain levels in neuromyelitis optica. Miyazawa I; Nakashima I; Petzold A; Fujihara K; Sato S; Itoyama Y Neurology; 2007 Mar; 68(11):865-7. PubMed ID: 17353477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]